Ascendis Pharma A/s Stock News

Ascendis Pharma A/S (NASDAQ: ASND ) announced topline data from its Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism (HP), a condition in which the body produces abnormally low levels of parathyroid hormone (PTH). 78.7% of TransCon PTH-treated patients achieved serum calcium levels in the normal range and independence from therapeutic levels of conventional therapy, compared to 4.8% for patients in the control … Full story available on Benzinga.com

Ascendis Pharma (ASND) said a phase 3 trial of TransCon PTH in adults with hypoparathyroidism ((HP)) met the main goal and all secondary objectives.HP is a condition in which the…

–  For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value <0.0001).

– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value <0.0001).

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on Invest

Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 6 1 0 0 Last

Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis NuCana plc (NASDAQ: NCNA) s

Shares of Ascendis Pharma (ASND) are down 7% in post-market trading even though its Q4 2021 results beat on the bottom line.

Ascendis Pharma AS Earnings, Revenue Beat in Q1

Ascendis Pharma press release (ASND): FY GAAP EPS of €7.00 beats by $15.44.Revenue of €7.77M (+11.8% Y/Y) misses by $0.13M.

- Top-line results from PaTHway, a Phase 3 randomized study evaluating the safety, tolerability, and efficacy of TransCon™ PTH in adult hypoparathyroidism (HP) patients on track for this quarter

- Top-line results from PaTHway, a Phase 3 randomized study evaluating the safety, tolerability, and efficacy of TransCon™ PTH in adult hypoparathyroidism (HP) patients on track for this quarter

Ascendis Pharma A/S' (ASND) CEO Jan Mikkelsen on Q4 2021 Results - Earnings Call Transcript